Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, InnoCare Pharma's Enterprise Value is $3,025.5 Mil.
InnoCare Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $12.1 Mil. Therefore, InnoCare Pharma's EV-to-OCF for today is 250.45.
The historical rank and industry rank for InnoCare Pharma's EV-to-OCF or its related term are showing as below:
INCPF'
s EV-to-OCF Range Over the Past 10 Years
Min: -214.54 Med: -5.6 Max: 254.03
Current: 254.03
During the past 9 years, the highest EV-to-OCF of InnoCare Pharma was 254.03. The lowest was -214.54. And the median was -5.60.
INCPF's EV-to-OCF is ranked worse than 99.01% of 1409
companies
in the Biotechnology industry
Industry Median: -3.68
vs INCPF: 254.03
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
InnoCare Pharma's PE Ratio (TTM) for today is calculated as:
InnoCare Pharma's share price for today is $1.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InnoCare Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
InnoCare Pharma EV-to-OCF Related Terms
InnoCare Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, InnoCare Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's EV-to-OCF falls into.
InnoCare Pharma's current Enterprise Value is $3,025.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InnoCare Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $12.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (INCPF) has a EV-to-OCF of 250.45 as of Aug. 23, 2026. According to the industry distribution chart, InnoCare Pharma ranks #1395 out of 1409 companies in the Biotechnology industry, placing it in the top 99%.
Is InnoCare Pharma's EV-to-OCF too high?
InnoCare Pharma's current EV-to-OCF is 250.45. Based on the distribution chart, InnoCare Pharma ranks #1395 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #1395 out of 1409 companies for EV-to-OCF. This places InnoCare Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. InnoCare Pharma's current EV-to-OCF is 250.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current EV-to-OCF of 250.45. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current EV-to-OCF is 250.45. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current EV-to-OCF is 250.45 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (INCPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.
Key valuation signals for INCPF:
EV-to-OCF: 250.45
GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for INCPF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCPF has been successfully added to your 
